GLP-1 Medications vs.
Orlistat: How the Options Compare

A percentage from one study is not a treatment ranking. The verified sources reviewed here do not include a randomized trial directly assigning people to current Wegovy or Zepbound versus Xenical or alli. Different participants, durations, lifestyle programs, products, and methods mean these studies cannot predict one person’s result or prove a “best” option. For other categories, see Luma Health’s guides to GLP-1 medicines versus bariatric surgery and GLP-1 medicines versus endoscopic sleeve gastroplasty.

What each option is—and what it changes

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors. Their current FDA labels describe use with a reduced-calorie diet and increased physical activity for long-term weight reduction and maintenance in adults with obesity, or adults with overweight plus at least one weight-related condition. The labels also contain other product-specific indications; those should not be treated as an all-purpose weight-management claim.^{[1] [2]}

Orlistat is a gastrointestinal lipase inhibitor. FDA explains that it binds enzymes that break down fats, so less dietary fat is absorbed from the digestive tract. Its effect is therefore tied directly to fat in meals, rather than to the incretin signaling pathways targeted by semaglutide or tirzepatide.^{[3] [4]}

Eligibility begins with the exact label and clinical context

NIDDK describes the common adult framework for prescription weight-management medicine as BMI of at least 30, or at least 27 with a weight-related health problem. That is a starting framework, not an automatic prescription. NIDDK also recommends weighing likely benefits, possible side effects, current health conditions and other medicines, family history, and cost with a health care professional.^[6]

Xenical’s professional information identifies its labeled population as people with BMI at least 30, or at least 27 with risk factors. Its label contraindicates pregnancy, chronic malabsorption syndrome, and cholestasis. Alli’s consumer label is for overweight adults 18 and older using a reduced-calorie, low-fat diet; it says not to use it if the user is not overweight, has diagnosed food-absorption problems, or takes cyclosporine.^{[3] [5]}

For Wegovy and Zepbound, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 is a contraindication. Both labels say the products are not recommended for severe gastroparesis. Pregnancy circumstances, diabetes medicines, gastrointestinal history, kidney status, and planned surgery or deep sedation can also change the conversation. A BMI threshold or an interest in a particular route does not settle suitability.^{[1] [2]}

What effectiveness evidence can—and cannot—compare

The prescription Xenical label summarizes five one-year placebo-controlled studies in which both groups received diet intervention. Mean loss was 13.4 pounds with Xenical plus diet and 5.8 pounds with placebo plus diet; the label reports a 3-percentage-point difference in mean percentage weight loss. These findings concern studied 120 mg Xenical—not alli 60 mg or a head-to-head comparison with Wegovy or Zepbound.^[3]

In STEP 1, 1,961 adults without diabetes received semaglutide 2.4 mg or placebo plus lifestyle intervention for 68 weeks. Mean change was −14.9% with semaglutide and −2.4% with placebo. In SURMOUNT-1, 2,539 adults without diabetes received studied tirzepatide regimens or placebo for 72 weeks. Mean changes ranged from −15.0% to −20.9% with tirzepatide and were −3.1% with placebo.^{[7] [8]}

Long-term planning matters for every route. NIDDK says duration depends on benefit and serious side effects, and effective, tolerated treatment may continue indefinitely. It also says people will probably regain some weight after stopping. Consider access, side effects, and what happens if treatment stops—not only the first follow-up.^[6]

The gastrointestinal effects are different—and so are the safety questions

Xenical’s most common adverse reactions include oily spotting, flatus with discharge, fecal urgency, fatty or oily stool, increased defecation, and fecal incontinence. Its label says gastrointestinal events may increase when the diet exceeds 30% of daily calories from fat. Alli likewise warns of gas with oily spotting, loose stools, and more frequent stools that can be difficult to control; a lower-fat diet lowers the chance of those changes.^{[3] [5]}

Orlistat can reduce absorption of fat-soluble vitamins and beta-carotene. Xenical calls for a multivitamin containing vitamins A, D, E, K, and beta-carotene; alli also directs a daily multivitamin. Both labels make medication review important: Xenical lists cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic, and antiretroviral medicines, while alli flags diabetes, thyroid, and seizure medicines.^{[3] [5]}

Wegovy and Zepbound commonly cause nausea, diarrhea, vomiting, constipation, and abdominal symptoms. Their labels warn about pancreatitis, gallbladder disease, volume-depletion-related kidney injury, severe gastrointestinal reactions, and serious hypersensitivity. Both labels describe aspiration reports with general anesthesia or deep sedation. These warnings require product-specific clinical guidance, not self-directed medication changes.^{[1] [2]}

In June 2026, FDA approved alli label changes warning of rare acute kidney injury and advised people with kidney disease or kidney stones to ask a clinician before use. FDA says the warning applies across approved orlistat products at both 60 mg and 120 mg. It lists back or groin pain, painful urination, blood in urine, swelling, or less frequent urination for prompt evaluation.^[4]

Brand-name evidence is not evidence for compounded GLP-1 products

The Wegovy and Zepbound labels and trials concern FDA-approved branded finished products. FDA says compounded GLP-1 drugs are not FDA approved and do not undergo FDA review for safety, effectiveness, or quality. FDA says compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug.^[9]

That distinction has practical consequences. FDA describes reported dosing errors, concerns involving different concentrations and multi-dose vials, shipping and storage problems, and products made with semaglutide salt forms that are different active ingredients from the semaglutide base used in approved drugs. Branded Wegovy or Zepbound results therefore do not establish the quality, safety, bioequivalence, effectiveness, or outcomes of a compounded preparation.^[9]

Cost, continuity, and a clinician-led decision

No comparable price or total-cost claim is made here. NIDDK states that some, but not all, insurance plans cover these medicines. Expenses vary by product, indication, insurance design, prior authorization, pharmacy, visits, laboratory needs, supplements, and follow-up. Ask for the complete recurring cost and what is included rather than relying on a headline price.^[6]

1. Which exact FDA-labeled product is being considered? Confirm whether it is prescription Xenical, OTC alli, branded Wegovy, branded Zepbound, or something else.
2. Which health and medication factors matter? Bring a current list of prescriptions, OTC products, supplements, kidney-stone or kidney history, gastrointestinal history, and pregnancy plans to the discussion.
3. What side effects would make the plan unsafe or impractical? Discuss bowel changes and nutrient monitoring with orlistat, and gastrointestinal symptoms, hydration, and product-specific monitoring with incretin medicines.
4. What is the continuation plan? Clarify refill or purchase access, follow-up, dietary support, how changes will be made safely, and what support is available if treatment cannot continue.
5. What is the verified total cost? Confirm coverage, product, pharmacy route, required visits, and any expected monitoring or supplement costs before beginning.

These questions support a shared decision, not a self-directed medication choice. A clinician can apply the label, medical history, current medicines, symptoms, and goals to the option under consideration. Visit Luma Health’s treatment information page or GLP-1 real-world effectiveness for related education.

Frequently asked questions